Furthermore, in breast cancer in particular, any moderating effect of Rab31 on EGFR signalling may well be completely muted by the fact that EGFR family receptor tyrosine kinase and their mutants are prevalent [130], or the activation of competing recycling pathways that will recycle endocytosed EGFR back to the surface [78]. Here, EGFR is linked to breast carcinoma.